PET/CT imaging in infectious conditions

Annals of the New York Academy of Sciences

Volumn 1228, Issue 1, 2011, Pages 150-166

  Israel, Ora ^a   Keidar, Zohar ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

FDG; Infection; PET CT

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GLUCOSE; GLUCOSE TRANSPORTER 1; IMMUNOSUPPRESSIVE AGENT; INDIUM 111; STEROID; TECHNETIUM 99M; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; AORTA ARCH SYNDROME; ARTHRITIS; ARTICLE; ASPERGILLOSIS; ATELECTASIS; BACTERIAL ENDOCARDITIS; BILIARY CIRRHOSIS; BONE INFECTION; BONE MARROW TRANSPLANTATION; BONE SCINTISCANNING; BRAIN CORTEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DIABETIC FOOT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISKITIS; DRUG UPTAKE; FIBROBLAST; FOLLOW UP; FRACTURE NONUNION; GASTROINTESTINAL TRACT; GIANT CELL ARTERITIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GRAFT INFECTION; HEART ABSCESS; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTIOUS ARTHRITIS; INFLAMMATION; INFLAMMATORY ARTHITIDES; KNEE PROSTHESIS; LEUKOCYTE COUNT; LUNG NODULE; LUNG SARCOIDOSIS; MACROPHAGE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MYCOTIC ANEURYSM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; ORGAN TRANSPLANTATION; OSTEOMYELITIS; PAIN; PATIENT MONITORING; PNEUMONIA; PROSTHESIS INFECTION; PYREXIA IDIOPATHICA; RADIATION DOSE; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; SOFT TISSUE INFECTION; SPINE SURGERY; SPONDYLITIS; STANDARD UPTAKE VALUE; STEROID THERAPY; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT; VASCULITIS; VIRUS LOAD;

EID: 79959785989     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06026.x     Document Type: Article

References (100)

1. Bleeker-Rovers, C.P., F.J. Vos, F.H. Corstens & W.J. Oyen 2008. Imaging of infectious diseases using [18F] fluorodeoxyglucose P.E.T. Q. J. Nucl. Med. Mol. Imaging. 52: 17-29.
2. Meller, J., C.O. Sahlmann & A.K. Scheel 2007. 18F-FDG PET and PET/CT in fever of unknown origin. J. Nucl. Med. 4: 35-45.
3. Bar-Shalom, R., N. Yefremov, L. Guralnik, et al 2003. Clinical performance of P.ET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J. Nucl. Med. 44: 1200-1209.
4. Rabkin, Z., O. Israel & Z. Keidar 2010. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. J. Nucl. Med. 51: 1015-1020.
5. Blockmans, D., D. Knockaert, A. Maes, et al 2001. Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin. Infect. Dis. 32: 191-196.
6. Wasselius, J., J. Malmstedt, B. Kalin, et al 2008. High 18F-FDG uptake in synthetic aortic vascular grafts on PET/CT in symptomatic and asymptomatic patients. J. Nucl. Med. 49: 1601-1605.
7. Knockaert, D.C., S. Vanderschueren & D. Blockmans 2003. Fever of unknown origin in adults: 40 years on. J. Intern. Med. 253: 263-275.
8. Petersdorf, R.G. 1992. Fever of unknown origin. An old friend revisited. Arch. Intern. Med. 152: 21-22.
9. Kjaer, A., A.M. Lebech, A. Eigtved & L. Hojgaard 2004. Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur. J. Nucl. Med. Mol. Imaging. 31: 622-626.
10. Landor, M. 1998. Clinical problem-solving. A hidden agenda. N. Engl. J. Med. 338: 46-50.
11. Bleeker-Rovers, C.P., E.M. de Kleijn, F.H. Corstens, et al 2004. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur. J. Nucl. Med. Mol. Imaging. 31: 29-37.
12. Bleeker-Rovers, C.P., F.J. Vos, E.M. de Kleijn, et al 2007. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 86: 26-38.
13. Buysschaert, I., S. Vanderschueren, D. Blockmans, et al 2004. Contribution of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever of unknown origin. Eur. J. Intern. Med. 15: 151-156.
14. Jaruskova, M. & O. Belohlavek 2006. Role of FDG-PET and PET/CT in the diagnosis of prolonged febrile states. Eur. J. Nucl. Med. Mol. Imaging 33: 913-918.
15. Vanderschueren, S., E. Del Biondo, D. Ruttens, et al 2009. Inflammation of unknown origin versus fever of unknown origin: two of a kind. Eur. J. Intern. Med. 20: 415-418.
16. Vos, F.J., C.P. Bleeker-Rovers, F.H. Corstens, et al 2006. FDG-PET for imaging of non-osseous infection and inflammation. Q. J. Nucl. Med. Mol. Imaging 50: 121-130.
17. Jones, H.A. 2005. Inflammation imaging. Proc. Am. Thorac. Soc. 2: 545-548, 513-514. Review.
18. Goo, J.M., J.G. Im, K.H. Do, et al 2000. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216: 117-121.
19. Bakheet, S.M., M. Saleem, J. Powe, et al 2000. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin. Nucl. Med. 25: 273-278.
20. Kalicke, T., A. Schmitz, J.H. Risse, et al 2000. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur. J. Nucl. Med. 27: 524-528.
21. de Winter, F., C. van de Wiele, D. Vogelaers, et al 2001. Fluorine-18 fluorodeoxyglucose-position emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. J. Bone. Joint. Surg. Am. 83-A: 651-660.
22. Termaat, M.F., P.G. Raijmakers, H.J. Scholten, et al 2005. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J. Bone Joint. Surg. Am. 87: 2464-2471.
23. De Winter, F., F. Gemmel, C. Van De Wiele, et al 2003. 18-Fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the postoperative spine. Spine (Phila Pa 1976) 28: 1314-1319.
24. Palestro, C.J., C. Love & T.T. Miller 2006. Infection and musculoskeletal conditions: imaging of musculoskeletal infections. Best Pract. Res. Clin. Rheumatol. 20: 1197-1218.
25. Stumpe, K.D., M. Zanetti, D. Weishaupt, et al 2002. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR Am. J. Roentgenol. 179: 1151-1157.
26. Gemmel, F., P.C. Rijk, J.M. Collins, et al 2010. Expanding role of 18F-fluoro-D-deoxyglucose PET and PET/CT in spinal infections. Eur. Spine. J. 19: 540-551.
27. Hochhold, J., H. Yang & H. Zhuang 2006. Application of 18F-fluorodeoxyglucose and PET in evaluation of diabetic foot. PET Clin. N. Am. 1: 123-130.
28. Palestro, C.J. & C. Love 2007. Radionuclide imaging of musculoskeletal infection: conventional agents. Semin. Musculoskelet. Radiol. 11: 335-352.
29. Keidar, Z., D. Militianu, E. Melamed, et al 2005. The diabetic foot: initial experience with 18F-FDG PET/CT. J. Nucl. Med. 46: 444-449.
30. Hopfner, S., C. Krolak, S. Kessler, et al 2004. Preoperative imaging of Charcot neuroarthropathy in diabetic patients: comparison of ring PET, hybrid PET, and magnetic resonance imaging. Foot Ankle Int. 25: 890-895.
31. Schwegler, B., K.D. Stumpe, D. Weishaupt, et al 2008. Unsuspected osteomyelitis is frequent in persistent diabetic foot ulcer and better diagnosed by MRI than by 18F-FDG PET or 99mTc-MOAB. J. Intern. Med. 263: 99-106.
32. Zhuang, H., H. Yang & A. Alavi 2006. Critical role of 18F-labeled fluorodeoxyglucose PET in the management of patients with arthroplasty. PET Clin. N. Am. 1: 99-106.
33. Manthey, N., P. Reinhard, F. Moog, et al 2002. The use of [18 F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl. Med. Commun. 23: 645-653.
34. Kwee, T.C., R.M. Kwee & A. Alavi 2008. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur. J. Nucl. Med. Mol. Imaging 35: 2122-2132.
35. Delank, K.S., M. Schmidt, J.W. Michael, et al 2006. The implications of 18F-FDG PET for the diagnosis of endoprosthetic loosening and infection in hip and knee arthroplasty: results from a prospective, blinded study. BMC Musculoskelet. Disord. 7: 20.
36. Kisielinski, K., U. Cremerius, P. Reinartz & F.U. Niethard 2003. Fluordeoxyglucose positron emission tomography detection of inflammatory reactions due to polyethylene wear in total hip arthroplasty. J. Arthroplasty. 18: 528-532.
37. De Winter, F., D. Vogelaers, F. Gemmel & R.A. Dierckx 2002. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur. J. Clin. Microbiol. Infect. Dis. 21: 247-257.
38. Schiesser, M., K.D. Stumpe, O. Trentz, et al 2003. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. Radiology 226: 391-398.
39. Hartmann, A., K. Eid, C. Dora, et al 2007. Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur. J. Nucl. Med. Mol. Imaging 34: 704-714.
40. Hustinx, R. & M.G. Malaise 2006. PET imaging of arthritis. PET Clin. N. Am. 1: 131-139.
41. Beckers, C., C. Ribbens, B. Andre, et al 2004. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J. Nucl. Med. 45: 956-964.
42. Gorenberg, M., R. Bar-Shalom & O. Israel 2008. Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br. J. Radiol. 81: 821-825.
43. Strobel, K. & K.D. Stumpe 2007. PET/CT in musculoskeletal infection. Semin Musculoskelet Radiol. 11: 353-364.
44. Zhuang, H., J.W. Sam, T.K. Chacko, et al 2003. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur. J. Nucl. Med. Mol. Imaging 30: 1096-1103.
45. Bandyk, D.F. & G.E. Esses 1994. Prosthetic graft infection. Surg. Clin. North Am. 74: 571-590.
46. Bandyk, D.F. 2005. Infection in prosthetic vascular grafts. In Vascular Surgery. 6th ed. R.B. Ratherford, Ed.: 875-894. Saunders. Philadelphia, PA.
47. Goldstone, J. & W.S. Moore 1974. Infection in vascular prostheses. Clinical manifestations and surgical management. Am. J. Surg. 128: 225-233.
48. Hallett, J.W., Jr., D.M. Marshall, T.M. Petterson, et al 1997. Graft-related complications after abdominal aortic aneurysm repair: reassurance from a 36-year population-based experience. J. Vasc. Surg. 25: 277-284.
49. Orton, D.F., R.F. LeVeen, J.A. Saigh, et al 2000. Aortic prosthetic graft infections: radiologic manifestations and implications for management. Radiographics 20: 977-993.
50. Vogel, T.R., R. Symons & D.R. Flum 2008. The incidence and factors associated with graft infection after aortic aneurysm repair. J. Vasc. Surg. 47: 264-269.
51. Calligaro, K.D., F.J. Veith, M.L. Schwartz, et al 1992. Are gram-negative bacteria a contraindication to selective preservation of infected prosthetic arterial grafts? J. Vasc. Surg. 16: 337-345.
52. Kolakowski, S., Jr., M.J. Dougherty & K.D. Calligaro 2007. Does the timing of reoperation influence the risk of graft infection? J. Vasc. Surg. 45: 60-64.
53. Malone, J.M., W.S. Moore, G. Campagna & B. Bean 1975. Bacteremic infectability of vascular grafts: the influence of pseudointimal integrity and duration of graft function. Surgery 78: 211-216.
54. Szilagyi, D.E., R.F. Smith, J.P. Elliott & M.P. Vrandecic 1972. Infection in arterial reconstruction with synthetic grafts. Ann. Surg. 176: 321-333.
55. Yashar, J.J., A.K. Weyman, R.J. Burnard & J. Yashar 1978. Survival and limb salvage in patients with infected arterial prostheses. Am. J. Surg. 135: 499-504.
56. Love, C. & C.J. Palestro 2004. Radionuclide imaging of infection. J. Nucl. Med. Technol. 32: 47-57.
57. Keidar, Z., A. Engel, A. Hoffman, et al 2007.Prosthetic vascular graft infection: the role of 18F-FDG PET/CT. J. Nucl. Med. 48: 1230-1236.
58. Fukuchi, K., Y. Ishida, M. Higashi, et al 2005. Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. J. Vasc. Surg. 42: 919-925.
59. Bruggink, J.L., A.W. Glaudemans, B.R. Saleem, et al 2010. Accuracy of FDG-PET-CT in the diagnostic work-up of vascular prosthetic graft infection. Eur. J. Vasc. Endovasc. Surg. 40: 348-354.
60. Spacek, M., O. Belohlavek, J. Votrubova, et al 2009. Diagnostics of "non-acute" vascular prosthesis infection using 18F-FDG PET/CT: our experience with 96 prostheses. Eur. J. Nucl. Med. Mol. Imaging 36: 850-858.
61. Ben-Haim, S., S. Gacinovic & O. Israel 2009. Cardiovascular infection and inflammation. Semin. Nucl. Med. 39: 103-114.
62. Choi, S.J., J.S. Lee, M.H. Cheong, et al 2008. F-18 FDG PET/CT in the management of infected abdominal aortic aneurysm due to Salmonella. Clin. Nucl. Med. 33: 492-495.
63. Spacek, M., P. Stadler, O. Belohlavek & P. Sebesta 2010. Contribution to FDG-PET/CT diagnostics and post-operative monitoring of patients with mycotic aneurysm of the thoracic aorta. Acta. Chir. Belg. 110: 106-108.
64. Belhocine, T., D. Blockmans, R. Hustinx, et al 2003. Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data. Eur. J. Nucl. Med. Mol. Imaging 30: 1305-1313.
65. Webb, M. & A. Al-Nahhas 2006. Molecular imaging of Takayasu's arteritis and other large-vessel vasculitis with 18F-FDG PET. Nucl. Med. Commun. 27: 547-549.
66. Amezcua-Guerra, L.M. & C. Pineda 2007. Imaging studies in the diagnosis and management of vasculitis. Curr. Rheumatol. Rep. 9: 320-327.
67. Otsuka, H., N. Morita, K. Yamashita & H. Nishitani 2007. FDG-PET/CT for diagnosis and follow-up of vasculitis. J. Med. Invest. 54: 345-349.
68. Walter, M.A., R.A. Melzer, C. Schindler, et al 2005. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur. J. Nucl. Med. Mol. Imaging 32: 674-681.
69. Both, M., K. Ahmadi-Simab, M. Reuter, et al 2008. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann. Rheum. Dis. 67: 1030-1033.
70. Sachdev, M., G.E. Peterson & J.G. Jollis 2002. Imaging techniques for diagnosis of infective endocarditis. Infect. Dis. Clin. North. Am. 16: 319-337, ix.
71. Yen, R.F., Y.C. Chen, Y.W. Wu, et al 2004. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis: a preliminary report. Acad. Radiol. 11: 316-321.
72. Van Riet, J., E.E. Hill, O. Gheysens, et al 2010. (18)F-FDG PET/CT for early detection of embolism and metastatic infection in patients with infective endocarditis. Eur. J. Nucl. Med. Mol. Imaging 37: 1189-1197.
73. Brust, D., M. Polis, R. Davey, et al 2006. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 20: 985-993.
74. O'Doherty, M.J., S.F. Barrington, M. Campbell, et al 1997. PET scanning and the human immunodeficiency virus-positive patient. J. Nucl. Med. 38: 1575-1583.
75. Sathekge, M., I. Goethals, A. Maes & C. van de Wiele 2009. Positron emission tomography in patients suffering from HIV-1 infection. Eur. J. Nucl. Med. Mol. Imaging 36: 1176-1184.
76. Mahfouz, T., M.H. Miceli, F. Saghafifar, et al 2005. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J. Clin. Oncol. 23: 7857-7863.
77. Jones, H.A., T. Donovan, M.J. Goddard, et al 2004. Use of 18FDG-pet to discriminate between infection and rejection in lung transplant recipients. Transplantation 77: 1462-1464.
78. Simons, K.S., P. Pickkers, C.P. Bleeker-Rovers, et al 2010. F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med. 36: 504-511.
79. Jasper, N., J. Dabritz, M. Frosch, et al 2010. Diagnostic value of [(18)F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation. Eur. J. Nucl. Med. Mol. Imaging 37: 136-145.
80. Gungor, T., I. Engel-Bicik, G. Eich, et al 2001. Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-D-glucose in children with chronic granulomatous disease. Arch. Dis. Child. 85: 341-345.
81. Sturm, E., E.H. Rings, E.H. Scholvinck, et al 2006. Fluorodeoxyglucose positron emission tomography contributes to management of pediatric liver transplantation candidates with fever of unknown origin. Liver Transpl. 12: 1698-1704.
82. Depas, G., T. Decortis, N. Francotte, et al 2007. F-18 FDG PET in infectious diseases in children. Clin. Nucl. Med. 32: 593-598.
83. Wyss, M.T., M. Honer, N. Spath, et al 2004. Influence of ceftriaxone treatment on FDG uptake-an in vivo [18F]-fluorodeoxyglucose imaging study in soft tissue infections in rats. Nucl. Med. Biol. 31: 875-882.
84. Bleeker-Rovers, C.P., R.G. de Sevaux, H.W. van Hamersvelt, et al 2003. Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am. J. Kidney. Dis. 41: E18-E21.
85. Reuter, S., A. Buck, B. Manfras, et al 2004. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 39: 509-517.
86. Hofmeyr, A., W.F. Lau & M.A. Slavin 2007. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberc. Edinb. 87: 459-463.
87. Kim, S.J., I.J. Kim, K.T. Suh, et al 2009. Prediction of residual disease of spine infection using F-18 FDG PET/CT. Spine (Phila Pa 1976) 34: 2424-2430.
88. Forstrom, L.A., B.P. Mullan, J.C. Hung, et al 2000. 18F-FDG labelling of human leukocytes. Nucl. Med. Commun. 21: 691-694.
89. Osman, S. & H.J. Danpure 1992. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int. J. Rad. Appl. Instrum. B. 19: 183-190.
90. Pellegrino, D., A.A. Bonab, S.C. Dragotakes, et al 2005. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J. Nucl. Med. 46: 1522-1530.
91. Forstrom, L.A., W.L. Dunn, B.P. Mullan, et al 2002. Biodistribution and dosimetry of [(18)F]fluorodeoxyglucose labelled leukocytes in normal human subjects. Nucl. Med. Commun. 23: 721-725.
92. Dumarey, N., D. Egrise, D. Blocklet, et al 2006. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J. Nucl. Med. 47: 625-632.
93. Rini, J.N., K.K. Bhargava, G.G. Tronco, et al 2006. PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology 238: 978-987.
94. Desouza, R.M., A. Prachalias, P. Srinivasan, et al 2009. Differentiation between infection in kidney and liver cysts in autosomal dominant polycystic kidney disease: use of PET-CT in diagnosis and to guide management. Transplant. Proc. 41: 1942-1945.
95. Palestro, C.J. 2009. Radionuclide imaging of infection: in search of the grail. J. Nucl. Med. 50: 671-673.
96. Dumarey, N. 2009. Imaging with FDG labeled leukocytes: is it clinically useful? Q. J. Nucl. Med. Mol. Imaging 53: 89-94.
97. Makinen, T.J., P. Lankinen, T. Poyhonen, et al 2005. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur. J. Nucl. Med. Mol. Imaging 32: 1259-1268.
98. Ujula, T., S. Salomaki, P. Virsu, et al 2009. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl. Med. Biol. 36: 631-641.
99. Nanni, C., C. Errani, L. Boriani, et al 2010. 68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. J. Nucl. Med. 51: 1932-1936.
100. Signore, A., V.A. Soroa & De Vries E.F. 2009. Radiolabelled white blood cells or FDG for imaging on inflammation and infection? Q. J. Nucl. Med. Mol. Imaging 53: 23-25.